EP Patent

EP3034496A1 — Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide

Assigned to Lek Pharmaceuticals dd · Expires 2016-06-22 · 10y expired

What this patent protects

The present invention relates to novel crystalline solvates of N -[2-[(1 S )-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1 H-isoindol-4-yl]acetamide and methods for their preparation. Furthermore, the invention concerns pharmaceutical compositions…

USPTO Abstract

The present invention relates to novel crystalline solvates of N -[2-[(1 S )-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1 H-isoindol-4-yl]acetamide and methods for their preparation. Furthermore, the invention concerns pharmaceutical compositions comprising an effective amount of one or more of the novel crystalline solvates and the use thereof as medicaments.

Drugs covered by this patent

Patent Metadata

Patent number
EP3034496A1
Jurisdiction
EP
Classification
—
Expires
2016-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Lek Pharmaceuticals dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.